Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...
As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer ...
[Editor’s note: The hacker requested that we remove the image for legal reasons, so it’s blurry now. We hope all’s well!] Lithium technology has ushered in a new era of batteries with exceptionally ...
After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...
Pharmaceutical Technology on MSN
Harbour BioMed and BMS sign multi-specific antibody collab
Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...
Biopharmaceutical firm Bristol Myers Squibb (BMS) and IT services company Accenture on Wednesday announced the opening of a ...
The latest Fujitsu AIRSTAGE Cloud BMS release, v3.1.4-R4, contains multiple updates and new tools to simplify commissioning ...
With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback